reports
Colruyt Group N.V: 1 director
A director at Colruyt Group N.V bought 3,100 shares at 38.460EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Michiel Declercq
- Baptiste Salaville
- Ghada Ben Sedrine
- Nicolas David
- Thomas Zlowodzki
- Baptiste Salaville
- Ghada Ben Sedrine
- Nicolas David
- Thomas Zlowodzki
- ING Helpdesk
- Kristof Samoy
Aalberts Key take-aways CMD – Thrive 2030 – Refocus, Rebalance, Rechar...
Yesterday Aalberts hosted its CMD ‘Thrive 2030' spanning the 2025-2030 strategy cycle building on the interplay between three axes: Refocus, Rebalance, Recharge. Refocus will drive growth through strengthened leadership in attractive markets and brings along disposals. Rebalance should double US exposure and bring equal weight to the three reporting segments (Building, Semicon & Industry). Recharge entails intensified operational excellence, continued innovation & M&A as growth accelerator. An u...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
- Robert Jan Vos
- Michiel Declercq
Colruyt 1H24/25: Competition weighs on sales, but reiterates guidance
Colruyt's HY24/25 comparable sales decreased by 2.0% to € 5.43bn, or well below kbcse of € 5.72m. The decline was mainly driven by the Colruyt banner due to unfavourable weather conditions, lower food inflation and declining market share. The sales pressure was however partially offset by further gross margin improvements. As such, the EBIT decline of 4.8% to € 245m came in above kbcse (€ 236m), and was also in line with the earlier guidance, with Colruyt already hinting for a limited EBIT decli...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Starts petrelintide phase 2b in overweight/...
Zealand announced that the first participant has been enrolled in the randomised, double-blind, placebo-controlled phase 2b trial of petrelintide (long acting amylin analog) in obesity or overweight + co-morbidities. We believe petrelintide is on track to achieve GLP-1-like weight loss in the phase 2b trial (we expect results in 2026), but with a better tolerability profile. In the meantime, we expect some read-through from the phase 3 results of CagriSema (GLP-1/amylin analog) expected in 4Q24...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREM...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity.The Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Completion of enr...
- Julian Dobrovolschi
- ING Helpdesk
- Kristof Samoy
Aalberts CMD with updated 2030 targets and adjusted segment reporting
Aalberts just issued a release ahead of today's CMD starting at 9.30am CET. While the previous strategy cycle (CMD Dec-21) ran from 2021-2026, the strategy cycle linked to today's CMD spans until 2030. As expected previous 2026 targets were reconfirmed, whilst fresh 2030 targets include a >€ 4.5bn revenue ambition and an EBITA margin >18%. Accumulate maintained.
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Martijn Den Drijver
Aalberts N.V.: Aalberts hosts 2024 capital markets day and sets 2030 o...
Aalberts N.V.: Aalberts hosts 2024 capital markets day and sets 2030 objectives Utrecht, 10 December 2024 key highlights on track and committed to realise 2026 objectivesintroducing long-term 2030 objectivesdrive profitable sustainable growth and enhance leadership positions by innovation, geographical expansion and accelerated portfolio optimisationdisciplined capital allocation with share buybackssimplified reporting structure with three business segments Aalberts ‘thrive 2030’ Aalberts will focus on leadership positions in three attractive end markets with high organic growth potenti...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Wim Lewi
- Kristof Samoy
Aalberts Upcoming CMD: focus on portfolio optimisation and foremost M&...
Next Tuesday Aalberts will be hosting its first CMD under the reins of the new CEO. In spite of headwinds in most of its important end markets we expect no surprise on current 2026 targets as management has been very vocal about their commitment to the targets set at the previous CMD in Dec-21. We look forward to seeing an update on portfolio optimisation as both disposals and M&A in the ongoing strategy cycle are so far -with 2 more years to go- falling short of communicated ambitions which wer...
- Emna Ben Bdira
- Maxime Kogge
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.